Clinical Trial Update: A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 pediatric trial evaluating Deucravacitinib (BMS-986165) for Juvenile Psoriatic Arthritis, assessing drug levels, efficacy, and safety; the study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Psoriatic Arthritis

Drugs mentioned

• Deucravacitinib (deucravacitinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Juvenile Psoriatic Arthritis | Phase 3 | Status: RECRUITING